Russia’s Sputnik Vaccine To Be Manufactured By Tibet’s TopRidge Pharma
The Russian Direct Investment Fund (RDIF) and China’s Tibetan based TopRidge Pharma have agreed to produce over 100 million doses of Russia’s anti-coronavirus vaccine Sputnik V annually in China, the Fund said on Thursday.
“The Russian Direct Investment Fund and TopRidge Pharma (a subsidiary company of one of China’s pharmaceutical market leaders, Tibet Rhodiola Pharmaceutical Holding) have agreed to cooperate on production of over 100 million doses per year of the world’s first registered vaccine against coronavirus Sputnik V in China.” the statement said.
TopRidge Pharma will be able to distribute the vaccine in mainland China, as well as in Hong Kong, Macao and Taiwan, subject to all appropriate regulatory approvals.
The amount of the vaccine that is produced will be sufficient to inoculate over 50 million people, according to the statement. Two shots of the vaccine are required for each individual treatment.
The parties also intend to cooperate on clinical trials of the vaccine in China and promotion of Sputnik V in the country. Sputnik V has been registered in 58 countries globally covering a population of over 1.5 billion people in total. Sputnik V’s efficacy is 91.6% as confirmed by the data published in the Lancet, one of the world’s oldest and most respected medical journals.
- Russia’s Sputnik V Vaccine Destined For EU Markets
- Russia Begins Global Ramp Up Of Covid-19 Sputnik V Vaccine
Russia Briefing is written by Dezan Shira & Associates. The firm has 28 offices throughout Eurasia, including China, Russia, India, and the ASEAN nations, assisting foreign investors into the Eurasian region. Please contact Maria Kotova at firstname.lastname@example.org for Russian investment advisory or assistance with market intelligence, legal, tax and compliance issues throughout Asia.